Navigation Links
Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments
Date:5/5/2008

ilable by mid-2009 and all Phase 3 data available in fall 2009. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

Albuferon(R): Treatment Phase of ACHIEVE 2/3 Completed; On Track with Timeline to Phase 3 Data and Filing of Marketing Applications

In April 2008, HGS completed the treatment phase of ACHIEVE 2/3, one of two Phase 3 trials of Albuferon (albinterferon alfa-2b) in combination with ribavirin in treatment-naive patients with chronic hepatitis C. The Company expects to complete the treatment phase of ACHIEVE 1 in July 2008. HGS is on track to have ACHIEVE 2/3 data available before the end of 2008, ACHIEVE 1 data by spring 2009 and the filing of global marketing authorizations by fall 2009. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

Data were presented in April in Milan at the 43rd Annual Meeting of the European Association for the Study of the Liver, which showed that Albuferon's pharmacodynamic characteristics and ability to maintain effective blood levels for a longer period of time than is seen with other long-acting interferons may make it an effective component of future combination treatment with novel antivirals for the treatment of chronic hepatitis C.

Oncology Portfolio Advances: Rights Reacquired to TRAIL Receptor Antibodies; Chemotherapy Combination Trial of HGS-ETR1 to Begin in Hepatocellular Cancer

In April, HGS reacquired rights to its TRAIL receptor antibodies HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab) from GSK in return for a reduction in royalties due to HGS if Syncria(R) (albiglutide) is commercialized. The fees and milestone payments due to HGS under the original Syncria agreement, some of which have already been received, could amount to as much as $183 million and remain unchanged in the amended agreement.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
2. China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex
3. Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2008 Financial Results
4. Identity Sciences Introduces a New, Fast Forensic Human I.D. Test
5. Human Genome Sciences Advances Oncology Portfolio
6. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
7. Human Pheromone Sciences Announces Quarterly and Full Year Results
8. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
9. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen Conference
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Lehman Brothers Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014 2014 Deep Research ... is a professional and in-depth research report on ... information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/21/2014)... Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... periods ended September 30, 2014.  Biorem,s complete 2014 third quarter financial ... Financial Summary:Three-months ended September 30, , Nine-months ... data) , 2014 , 2013 , ... , 5,281 , 6,715 , 14,476 ...
(Date:11/18/2014)... CA (PRWEB) November 17, 2014 Athena Signature ... Salk , Dr. Beverly Emerson, a professor in the Regulatory ... genes. Her most recent discovery points to an “off switch” ... Emerson’s career and how her local research is making a ... present her findings and then join host Cheryl K. Goodman, ...
(Date:11/18/2014)... (PRWEB) November 18, 2014 Array Architects ... and design expertise to the nation's hospitals and health ... served by those dedicating their careers to the advancement ... respected contributor in her respective field, Laura Silvoy has ... at the 2014 Winter Simulation Conference. , Laura ...
Breaking Biology Technology:Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2
... Because I used to be a corporate HR person, people ask me ... question that I get asked is: Can my company actually do that? ... did anyway. , ,Im not a lawyer. I dont send people off ... so far). Life is long. So many of these errors are clueless ...
... moved to speed up information access for officers, with the ... Aladdin Knowledge Systems . , ,It has proven to provide ... officers, who are now free to focus on protecting the ... information, said Neil Sullivan, the companys enterprise security regional manager. ...
... Stem Cell MADISONIn the first debate of Wisconsin's ... scientific research using human embryonic stem cells as little ... the 99 percent of stem cell research that uses ... the 1 percent that uses human embryonic stem cells. ...
Cached Biology Technology:Illegal business tricks: Can my company do that? 2Illegal business tricks: Can my company do that? 3Madison police adopt digital lock and key 2It's 99 percent certain: Research cannot rely on adult stem cells alone 2It's 99 percent certain: Research cannot rely on adult stem cells alone 3
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and ... "Cell Therapy - Technologies, Markets and Companies" to ... cell therapy technologies and methods, which have already started to ... stem cell transplantation is replacing the old fashioned bone marrow ... Cell therapy is bound to become a part of medical ...
(Date:11/3/2014)... from Australia report that low birth weight and preterm ... hip replacements in adulthood. Findings published in the American ... Research , indicate that low birth weight and pre-term ... due to OA as adults. , According to ... 25 are diagnosed with clinical OA. Symptoms of OA ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2
... Results from Parascript SignatureXpert confirm that signatures on financial ... Moscow to initiate forensic examination and expert study ... Colo., June 22 Parascript, LLC, the ... that it has partnered with the Moscow Law Firm ...
... June 29 Kornberg Associates | Architects ( www.kornberg.com ... to design a new Cognitive & Neurobiological Imaging Center. ... firm has worked with Stanford University since 1980 ... one of which is the two-story, 32,000 square-foot office building ...
... Eight supply chain professionals were elected in June by the ... the seven existing members of SCC,s board. Newly elected board members, ... as follows: , , , , ... Hewlett Packard , Jane Barrett, Research ...
Cached Biology News:Parascript Signature Verification Technology Used by Moscow Law Firm to Detect Signature Fraud in $160,000 Debt Collection Case 2Parascript Signature Verification Technology Used by Moscow Law Firm to Detect Signature Fraud in $160,000 Debt Collection Case 3Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2
Chlamydia pneumoniae (TWAR)...
Prostaglandin-E2 receptor EP2/EP3 Market Segment: GPCRs...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: